HEM Hemostemix Inc.

0.0210USD0.0300 CAD · TSXV-14.29%Mkt Cap: 4.43M USDP/E: —

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II…

Key Statistics

Company
Market Cap4.43M USD
Enterprise Value6.79M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-3.30M USD
Revenue/Share—
Last Price0.0210 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryCA
SectorHealthcare
IndustryBiotechnology
ISINCA4236943060
Valuation
P/E (Trailing)—
P/E (Forward)-0.21
PEG—
EV/EBITDA-1.92
EV/Revenue—
P/S—
P/B-1.07
EPS (TTM)-0.02 USD
EPS (Forward)-0.10 USD
52W Range
0.02100% of range0.0769
52W High0.0769 USD
52W Low0.0210 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE94.80%
ROA-556.61%
ROIC—
ROCE—
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.17M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-54.33%
Net Debt2.35M USD
Net Debt/EBITDA-0.67
Net Debt/FCF—
Balance Sheet
Debt/Equity-0.72
Current Ratio0.13
Quick Ratio0.13
Book Value/Sh-0.02 USD
Cash/Share0.0007 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay DateDec 30, 2020
Splits
Last Split1:20
Split DateDec 30, 2020
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.211.44M
Float168.41M
Insiders16.05%
Institutions0.00%
Short Interest
Short Ratio0.0d
Short % Out.0.00%
Shares Short1.13K
Short (prev mo.)438
Technical
SMA 500.0416 (-49.6%)
SMA 2000.0458 (-54.2%)
Beta0.71
S&P 52W Chg12.00%
Avg Vol (30d)82.93K
Avg Vol (10d)171.58K
Technical Indicators
RSI (14)20.8
MACD-0.0071
MACD Signal-0.0051
MACD Hist.-0.0020
BB Upper0.0468 USD
BB Middle0.0346 USD
BB Lower0.0224 USD
BB Width70.47%
ATR (14)0.0044 USD
Vol Ratio (20d)0.10x

About Hemostemix (CVE: HEM)

›

Hemostemix (CVE: HEM) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.

The shares were at 0.0300 CAD on 19 November 2026, down 72.7% over 52 weeks. Its 52-week range is 0.0300 CAD to 0.1100 CAD, and it trades at the bottom of that range.

Its market capitalisation is 6.34M CAD.

Hemostemix reports return on equity of 94.8% and an operating margin of 0.0%.

Its debt exceeds its cash by 3.37M CAD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 27 November 2026.